reading half-life threads from 2024 and half of it aged badly
Something I keep coming back to: reading half-life threads from 2024 and half of it aged badly.
Long half-life in this class comes from structural modification that promotes albumin binding and resists enzymatic degradation. Weekly dosing is a consequence of the molecule, not a convenience decision.
GIP receptor biology is genuinely unsettled — there is a live argument about agonism versus antagonism at the receptor — and the clinical results are robust regardless, which is an uncomfortable and interesting position.
Tolerance to the gastric effect develops with continued exposure while the appetite effect largely persists. That single fact explains most of the "it settles but it still works" pattern the side-effect board reports.
Ask me anything specific. Anything general I will probably get wrong.
best — the order this archive was captured in
GLP-1 receptor agonism acts both peripherally — insulin secretion in a glucose-dependent way, slowed gastric emptying — and centrally, on appetite regulation. The central component is the better explanation for sustained intake reduction.
Careful — you have a plausible mechanism and no evidence that it is the operative one in the case you are describing.
Careful — you have a plausible mechanism and no evidence that it is the operative one in the case you are describing.
Disagreeing with this specific inference — that is a preclinical result being read as human pharmacology.
Yes. The central component is the one that explains the reports on this site better than gastric emptying does.
Does the effect persist with continued dosing or does tolerance develop?
preclinical is not clinical and rodents are not small people
a mechanism you can state is not a mechanism you have demonstrated
Careful — you have a plausible mechanism and no evidence that it is the operative one in the case you are describing.
Adding the caveat the paper itself makes in its limitations section, which is stronger than anything in this thread.
The incretin effect is the observation that oral glucose provokes a larger insulin response than intravenous glucose at matched glycaemia, and the difference is mediated by gut hormones. That is the foundation the whole class sits on.
Went looking for human data on a mechanism everybody here asserts. Found preclinical work and one small study. That was clarifying.
Correcting my own comment: I attributed that to the GIP arm and the paper attributes it to the GLP-1 arm.
- 1Careful — you have a plausible mechanism and no evidence that it is the…7 comments in this branch · started by u/elodie_grimaldi